Stock Analysis, Dividends, Split History

SRNE / Sorrento Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)504.87
Enterprise Value ($M)480.89
Book Value ($M)254.37
Book Value / Share2.18
Price / Book1.98
NCAV ($M)-138.31
NCAV / Share-1.18
Price / NCAV-3.65
Share Statistics
Common Stock Shares Outstanding 82,903,567
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 87,434,049
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.03
Return on Equity (ROE)0.14
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.39
Income Statement (mra) ($M)
Revenue From Grants206,000.00
Reimbursement Revenue0.00
Sales Revenue Services Net11,269,000.00
Licenses Revenue140,381,000.00
Operating Income25.34
Net Income11.11
Earnings Per Share Basic0.13
Earnings Per Share Diluted0.13
Cash Flow Statement (mra) ($M)
Cash From Operations-99.18
Cash from Investing-16.53
Cash from Financing-16.53
Identifiers and Descriptors
Central Index Key (CIK)850261
Related CUSIPS
83587F902 83587F103 83587F952

Split History

Stock splits are used by Sorrento Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
SRNE : Sorrento Therapeutics Stock Analysis and Research Report

2017-11-04 - Asif

At its core, Sorrento Therapeutics is an antibody-centric company and leverage its proprietary G-MAB™ library and targeted delivery modalities to generate the next generation of cancer therapeutics. The company's validated fully human antibodies include PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, CCR2, OX40, TIGIT and CD137 among others. The company's vision is to leverage these antibodies in conjunction with proprietary targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary antibody drug conjugates (“ADCs”), bispecific approaches, as well as TCR-like antibodies. With LA Cell, Inc. (“LA Cell”), its joint venture with City of Hope, its objective is to become the global leader in the development of antibodies against intracellular targets such as STAT3, mutant KRAS, MYC, p53 and TAU. Additionally, Sorrento Therapeutics has acquired and are assessing the regulatory and strategic path forward for its portfolio of late ...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

7 Lucrative Biotech Stocks With Up to 300% Upside

2018-09-06 investorplace
Forget market dynamics. These biotechs are playing to their own tune. According to the Street’s top analysts this can be a very lucrative path. Biotech stocks can spike massively on positive news — be it key trial results or regulatory approvals. Of course, the opposite is also true and the biotech sector can crash just as quickly on unexpected disappointments. (38-5)

You Should Buy Sorrento Before It Reaches New Highs

2018-08-07 seekingalpha
Sorrento Therapeutics is an opportunity for investors that want a growth stock at a reasonable price. (24-3)

Your Daily Pharma Scoop: Eagle Gets New Patent, Ocular Refiles NDA, Antibe's Phase 2b Data Announced

2018-07-05 seekingalpha
Discussion: Eagle Pharmaceuticals Inc. (EGRX) is a specialty pharmaceutical company focused on developing and commercializing injectable products for oncology and critical care segments. The lead candidate of the company, Bendeka (bendamustine hydrochloride), received the U.S. Patent No. 10,010,533. The patent covers the drug’s use in blood cancer. The IP of the company now goes up to 15 patents. Teva Pharma (NYSE:TEVA) owns exclusive U. (63-1)

TRIGR Therapeutics Licenses Oncology Asset from ABL Bio in $554.3 Million-Plus Deal

2018-07-03 biospace
TRIGR Therapeutics, based in Irvine California, signed a deal with South Korean company ABL Bio Corporation. TIRGR is licensing the global commercial rights to ABL Bio’s pipeline of antibodies to treat cancer. (32-0)

Loncar Cancer Immunotherapy Index Reshuffles Listed Companies

2018-06-20 biospace
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight. (310-6)

CUSIP: 83587F202